Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 7 Issue 4

Comparative Study of Interleukin-6, Interleukin-1B Levels and Iron Profile Among Sudanese Rheumatoid Arthritis Patients with Iron Deficiency Anemia

Rouaa Babikir Ahmed1*, Khalid Mohamed Khalid Elhussain1,2, Babiker Ahmed Mohammed3, Doaa Abdullah Gasim4, Elyasaa Ahmed Gubartalla Ali5, Manal Mohammed Khalid Elhussien6, Nora Nahal Bouderba7, Mohammed Babiker Omer8, Rufaida Abdalla Ahmed9, Khalid Babikir Ahmed10and Ahmed Babekir Abdalla11

1Omdurman Islamic University, Faculty of Medical Laboratory Sciences, Sudan
2Omdurman Ahlia University, Faulty of Medicine, Sudan
3Karary University, Faculty of Medical Laboratory Sciences, Sudan
4International University of Africa, Sudan
5Institute of Endemic Diseases (IEND), Khartoum University, Sudan
6Al-Mughtaribeen University, Faulty of Medicine, Sudan
7University Tahri Mohammed, Faculty of Sciences of Nature and Life, Biology Department, Bechar, Algeria
8Al-Neelain University, Faculty of Medical Laboratory Science, Sudan
9Royal Bournemouth Hospital, Bournemouth, Dorset, UK
10,11Modern Medical Center, Khartoum, Sudan

*Corresponding Author: Rouaa Babikir Ahmed, Omdurman Islamic University, Faculty of Medical Laboratory Sciences, Sudan.

Received: February 21, 2023; Published: March 02, 2023


Aims: This study aimed to evaluate IL-6 and IL-1B levels and the iron profile (serum iron, ferritin, TIBC and TS%) in rheumatoid arthritis Sudanese patients.

Study Design: Case control. study.

Place and Duration of Study: This study was conducted at the Omdurman Islamic University, Sudan between 2018 and 2021.

Methodology: This study was conducted on 63 RA patients and 63 healthy individuals as control between 2018 and 2021. ELISA were used to measure the levels of IL-6and IL-1B, while the iron profile were carried out using automated chemical analyzer, the Transferrin saturation percentage TS% was calculated using the formula: TS (%)= [serum iron (ug/dl)/serum transferring (mg/dl)]17.

Result: IL-6 and IL1B levels were increased in anemic RA patients. In all patients, 98.4% of IL-6 levels and 28.5% of IL-1B levels had risen. IDA was common with 77% of anemic RA patients, their serum iron, ferritin and TS% show significant decrease. There was significant negative correlation between serum iron, ferritin, TIBC, and TS% with IL-6 in RA patients. There was statistically significant positive correlation between serum iron and IL1B in RA patients group.

Conclusion: The levels of IL-1β, IL-6 increased in RA patients and IDA showed 77% in case while there was association between IL-1β, IL-6 and serum iron in case. IDA is the most common and serious blood abnormality seen in RA. All of the above makes IL-1β, IL-6 and IDA with pivotal role in the pathophysiology of RA and this may affect the desirable option in the treatment of RA.

 Keywords: Interleukin-6 (IL-6); Interleukin-1B (IL-1B); Rheumatoid Arthritis (RA); Enzyme-linked Immunosorbent Assay (ELISA); Transferrin Saturation Percentage (TS%); Total Iron Binding Capacity (TIBC); Iron Deficiency Anemia (IDA)


  1. Samia M Abd El-Monema., et al. “Association of rheumatoid arthritis disease activity, severity with electrocardiographic findings, and carotid artery atherosclerosis”. Egyptian Rheumatology and Rehabilitation 46 (2019): 11-20.
  2. Iain B McInnes and Georg Schett. “Cytokines in the pathogenesis of rheumatoid arthritis”. Nature Reviews Immunology l7 (2007): 429-42.
  3. Fionula Brennan and Jonathan Beech. “Update on cytokines in rheumatoid arthritis”. Current Opinion in Rheumatology 3 (2007): 296-301.
  4. L C Huber., et al. “Synovial fibroblasts: Key players in rheumatoid arthritis”. Rheumatology 6 (2006): 66975.
  5. Zoltán Szekanecz., et al. “Macrophages and their products in rheumatoid arthritis”. Current Opinion in Rheumatology 3 (2007): 289-295.
  6. R Madhok., et al. “Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity”. Annals of the Rheumatic Diseases 3 (1993): 232-234.
  7. Lene S Knudsen., et al. “Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis”. Biomarkers1 (2008): 59-78.
  8. Francis K., et al. “A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal anti- inflammatory drugs through the entire GI tract”. Journal of Rheumatology1 (2010): 167-174.
  9. Christoph Sucker. “The Heyde syndrome: proposal for a unifying concept explainingnthe association of aortic valve stenosis, gastrointestinal angiodysplasia and bleeding”. International Journal of Cardiology 1 (2007): 77-78.
  10. Jaroslav Truksa., et al. “Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9”. British Journal of Haematology1 (2007): 138-147.
  11. M Feldmann., et al. “Role of cytokines in rheumatoid arthritis”. Annual Review of Immunology 14 (1996): 397-440.
  12. Tsuyoshi Kasama., et al. “Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis”. International Immunopharmacology 35 (2016): 301-306.
  13. M Chabaud., et al. “Human interleukin-17: a T cell-derived pro inflammatory cytokine produced by the rheumatoid synovium”. Arthritis and Rheumatology5 (1999): 963-970.
  14. Jean-Michel Dayer and Barry Bresnihan. “Targeting interleukin-1 in the treatment of rheumatoid arthritis”. Arthritis and Rheumatology3 (2002): 574-578.
  15. R Horai., et al. “Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice”. Journal of Experimental Medicine2 (2000): 313-320.
  16. Misato Hashizume and Masahiko Mihara. “The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis”. Hindawi Publishing Corporation Arthritis (2011): 8.
  17. Theodoros Eleftheriadis., et al. “Which is the best way for estimating transferrin saturation?”. Renal Failure 32 (2010): 8.
  18. W P Arend and J M Dayer. “Cytokines and cytokines antagonists in RA”. Arthritis and Rheumatology3 (1990): 305-315.
  19. Srinivasan Srirangan and Ernest H Choy. “The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis”. Therapeutic Advances in Musculoskeletal Disease5 (2010): 247-256.
  20. Cathrin Nikolaisen., et al. “Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality”. The Journal of Rheumatology 35 (2008): 380-386.
  21. Olga M Koper-Lenkiewicz., et al. “Could IL-1β, IL-6, IFN-γ, and sP-selectin serum levels be considered as objective and quantifable markers of rheumatoid arthritis severity and activity”. Reumatologia1 (2011): 16-25.
  22. Abbas Sabbar Dkhil and Musa Nima Mezher. “Association Between Interleukin-6 (IL-6) and Iron Status in Rheumatoid Arthritis Patients”. Journal of Life Sciences5 (2014): 404-409.
  23. Abbas Sabbar Dakhil. “Association of Serum Concentrations of Proinflammatory Cytokines and Hematological parameters in Rheumatoid Arthritis Patients”. Journal of Pharmaceutical Sciences and Research 10 (2019): 1966-1974.
  24. Eman Tariq Ali., et al. “A Comparative Study of Interleukin 6, Inflammatory Markers, Ferritin, and Hematological Profile in Rheumatoid Arthritis Patients with Anemia of Chronic Disease and Iron Deficiency Anemia”. Hindawi Anemia (2019): 7.
  25. Adeel Gulzar Chaudhary. “IL-1B Gene Polymorphism and Susceptibility to Rheumatoid Arthritis in Ethnic Saudi Patients”. World Applied Sciences Journal4 (2008): 449-4544.
  26. Michael H SchiV. “Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis”. Annals of the Rheumatic Diseases 59 (2000): i103-108.
  27. Dongjun Dai., et al. “A comprehensive meta-analysis of the association between three IL1B polymorphisms and rheumatoid arthritis”. Advances in Bioscience and Biotechnology 5 (2014): 108-116ABB.
  28. Rami M Elshazli., et al. “Genetic polymorphisms of ACE I/D, IL-1β G > A and IL-4 VNTR among Egyptian subjects with rheumatoid arthritis”. Archives of Physiology and Biochemistry (2019).
  29. Smyrnova Ganna. “The prevalence of anemia in rheumatoid arthritis”. Revista Brasileira de Reumatologia 4 (2014): 257-259.
  30. Fionula M Brennan and Iain B McInnes. “Evidence that cytokines play a role in rheumatoid arthritis”. Journal of Clinical Investigation 11 (2008): 3537-3545.
  31. J Weber., et al. “Decreased iron absorption in patients with active rheumatoid arthritis, with and without iron deficiency”. Annals of the Rheumatic Diseases 47 (1988): 404-409.
  32. WAHEED A., et al. “Iron Status in Rheumatoid Arthritis”. Annals of King Edward Medical University1 (2017).
  33. Noha Mohamed Saeed., et al. “Evaluation of Iron Profile in Sudanese with Rheumatoid Arthritis”. Journal of Medical and Biological Science3 (2016): 44-48.
  34. Tahani Mursal., et al. “Differential diagnosis of anemia in rheumatoid arthritis sudanese patients”. World Journal of Pharmaceutical and Medical Research WJPMR4 (2016): 01-04.
  35. A Zoli., et al. “Serum transferrin receptors in rheumatoid arthritis”. Annals of the Rheumatic Diseases 53 (1994): 699-701.
  36. Maha F Yacoub., et al. “Effect of Interleukin and Hepcidin in Anemia of Chronic Diseases Hindawi” (2020): 5.
  37. Fernando Gomollón and Javier P Gisbert. “Anemia and inflammatory bowel diseases”. World Journal of Gastroenterology37 (2009): 4659-4665.
  38. Robert T and Means Jr. “Hepcidin and anemia”. Blood Review4 (2004): 219-225.
  39. L L Moldawer., et al. “Cachectin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo”. FASEB Journal5 (1989): 1637-1643.
  40. Gaël Nicolas., et al. “The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation”. Journal of Clinical Investigation7 (2002): 1037-1044.
  41. Justyna Fryc and Stanisław Sierakowski. “Anaemia of chronic diseases in rheumatoid arthritis”. Rheumatology 48 (2010): 421-424.
  42. P V Voulgari., et al. “Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis”. Clinical Immunology2 (1999): 153-160.
  43. Guenter Weiss and Lawrence T. “Goodnough. Anemia of chronic disease”. The New England Journal of Medicine 10 (2005): 1011-1023.
  44. W TAŃSKI., et al. “Iron metabolism in patients with rheumatoid arthritis”. European Review for Medical and Pharmacological Sciences 25 (2021): 4325-4335.


Citation: Rouaa Babikir Ahmed., et al. “Comparative Study of Interleukin-6, Interleukin-1B Levels and Iron Profile Among Sudanese Rheumatoid Arthritis Patients with Iron Deficiency Anemia”.Acta Scientific Medical Sciences 7.4 (2023): 29-35.


Copyright: © 2022 Rouaa Babikir Ahmed., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US